Added to YB: 2023-12-12
Pitch date: 2023-12-12
ELYM [bullish]
Climb Bio, Inc.
+17.65%
current return
Author Info
Clark Street Value is a special sits/event-driven investor. Sign up for the newsletter.
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases.
Market Cap
$129.6M
Pitch Price
$2.55
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.82
P/E
-2.53
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Show full summary:
Eliem Therapeutics: Broken Biotech, Reverse Merger Risk
ELYM: Biotech with paused CNS programs due to capital constraints. Workforce cut 55%+, exploring strategic options. No debt, $100M cash, 49% owned by RA Capital. RA chair suggests reverse merger likely. IP may have value for ETX-155 Phase 2. Disclosure: Author owns shares.
Read full article (1 min)